• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉莫三嗪与异构联吡啶的两种新型共晶及其共结晶的原位监测。

Two novel cocrystals of lamotrigine with isomeric bipyridines and in situ monitoring of the cocrystallization.

机构信息

School of Chemical Engineering and Technology, Tianjin University, Tianjin, China; The Co-Innovation Center of Chemistry and Chemical Engineering of Tianjin, Tianjin University, Tianjin, China.

School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.

出版信息

Eur J Pharm Sci. 2017 Dec 15;110:19-25. doi: 10.1016/j.ejps.2017.06.001. Epub 2017 Jun 3.

DOI:10.1016/j.ejps.2017.06.001
PMID:28587788
Abstract

Crystal engineering strategy was applied to develop new solid forms of lamotrigine. Two novel cocrystals of lamotrigine forming with 4,4'-bipyridine (2:1) and 2,2'-bipyridine cocrystal (1:1.5) were successfully obtained by neat grinding and liquid assisted grinding. The novel cocrystals were fully characterized and confirmed by X-ray diffraction, thermal and spectroscopic analysis. DXRxi Raman microscope was also used to identify the cocrystals. The factors such as solvent and the structure of coformers which influenced the cocrystal formation were discussed. Furthermore, the novel cocrystals were both obtained by slurry crystallization. Process analytical technologies including focused beam reflectance measurement and attenuated total reflectance Fourier Transform Infrared were applied to investigate the cocrystallization process and the mechanism. HPLC analysis showed that the dissolution rate and the solubility of the two novel cocrystals were both improved.

摘要

晶体工程策略被应用于开发拉莫三嗪的新固体形式。通过干法研磨和液辅助研磨成功获得了拉莫三嗪与 4,4'-联吡啶(2:1)和 2,2'-联吡啶共晶(1:1.5)的两种新型共晶。通过 X 射线衍射、热分析和光谱分析对新型共晶进行了充分的表征和确认。还使用 DXRxi 拉曼显微镜来鉴定共晶。讨论了影响共晶形成的因素,如溶剂和共晶形成物的结构。此外,通过浆态结晶也获得了这两种新型共晶。应用聚焦光束反射测量和衰减全反射傅里叶变换红外等过程分析技术研究了共晶化过程和机制。HPLC 分析表明,两种新型共晶的溶出速率和溶解度均得到提高。

相似文献

1
Two novel cocrystals of lamotrigine with isomeric bipyridines and in situ monitoring of the cocrystallization.拉莫三嗪与异构联吡啶的两种新型共晶及其共结晶的原位监测。
Eur J Pharm Sci. 2017 Dec 15;110:19-25. doi: 10.1016/j.ejps.2017.06.001. Epub 2017 Jun 3.
2
Structural characterization and dissolution profile of mycophenolic acid cocrystals.霉酚酸共晶体的结构表征与溶出曲线
Eur J Pharm Sci. 2017 May 1;102:140-146. doi: 10.1016/j.ejps.2017.02.035. Epub 2017 Feb 28.
3
Drug-drug cocrystals of antituberculous 4-aminosalicylic acid: Screening, crystal structures, thermochemical and solubility studies.抗结核药物对氨基水杨酸的药物-药物共晶体:筛选、晶体结构、热化学及溶解度研究
Eur J Pharm Sci. 2017 Mar 1;99:228-239. doi: 10.1016/j.ejps.2016.12.016. Epub 2016 Dec 20.
4
Novel Aceclofenac Cocrystals with l-Cystine: Virtual Coformer Screening, Mechanochemical Synthesis, and Physicochemical Investigations.新型 Aceclofenac 与 l-胱氨酸共晶:虚拟共晶筛选、机械化学合成及理化性质研究。
Curr Drug Deliv. 2021;18(1):88-100. doi: 10.2174/1567201817666200817110949.
5
A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram.一种无需知晓化学计量比即可生成药物共晶体的新策略:杨梅素共晶体及三元相图
Pharm Res. 2015 Jan;32(1):47-60. doi: 10.1007/s11095-014-1443-y. Epub 2014 Jun 18.
6
Cocrystals of acyclovir with promising physicochemical properties.具有良好物理化学性质的阿昔洛韦共晶体。
J Pharm Sci. 2015 Jan;104(1):98-105. doi: 10.1002/jps.24248. Epub 2014 Nov 18.
7
Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties.吡罗昔康与酚类共晶形成物的共晶:制备、表征和溶解性能。
Pharm Dev Technol. 2019 Feb;24(2):199-210. doi: 10.1080/10837450.2018.1455210. Epub 2018 Apr 4.
8
Interrelation of the dissolution behavior and solid-state features of acetazolamide cocrystals.乙酰唑胺共晶体的溶解行为与固态特征的相互关系。
Eur J Pharm Sci. 2017 Jan 1;96:299-308. doi: 10.1016/j.ejps.2016.09.025. Epub 2016 Sep 17.
9
Development of a pharmaceutical cocrystal with solution crystallization technology: Preparation, characterization, and evaluation of myricetin-proline cocrystals.采用溶液结晶技术制备药物共晶体:杨梅素-脯氨酸共晶体的制备、表征与评价
Eur J Pharm Biopharm. 2016 Oct;107:151-9. doi: 10.1016/j.ejpb.2016.07.008. Epub 2016 Jul 6.
10
Novel furosemide cocrystals and selection of high solubility drug forms.新型呋塞米共晶及其高溶解性药物形式的选择。
J Pharm Sci. 2012 Feb;101(2):664-80. doi: 10.1002/jps.22805. Epub 2011 Nov 11.

引用本文的文献

1
A review on advancement of cocrystallization approach and a brief on screening, formulation and characterization of the same.共结晶方法的进展综述及其筛选、制剂和表征简述。
Heliyon. 2024 Apr 1;10(7):e29057. doi: 10.1016/j.heliyon.2024.e29057. eCollection 2024 Apr 15.
2
Exploring the Supramolecular Interactions and Thermal Stability of Dapsone:Bipyridine Cocrystals by Combining Computational Chemistry with Experimentation.通过计算化学与实验相结合探索氨苯砜:联吡啶共晶体的超分子相互作用和热稳定性
Cryst Growth Des. 2023 May 3;23(6):4638-4654. doi: 10.1021/acs.cgd.3c00387. eCollection 2023 Jun 7.
3
Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems.
设计共晶体:一种解决原料药问题的合理共形成物选择方法。
Pharmaceutics. 2023 Apr 6;15(4):1161. doi: 10.3390/pharmaceutics15041161.
4
Expanding the Solid Form Landscape of Bipyridines.拓展联吡啶的固态形式格局
Cryst Growth Des. 2021 Dec 1;21(12):7201-7217. doi: 10.1021/acs.cgd.1c01045. Epub 2021 Nov 10.
5
Mechanochemistry: A Green Approach in the Preparation of Pharmaceutical Cocrystals.机械化学:制备药物共晶体的绿色方法。
Pharmaceutics. 2021 May 25;13(6):790. doi: 10.3390/pharmaceutics13060790.
6
Development, Characterization, and in-vivo Pharmacokinetic Study of Lamotrigine Solid Self-Nanoemulsifying Drug Delivery System.拉莫三嗪固体自纳米乳化药物递送系统的研制、表征及体内药代动力学研究
Drug Des Devel Ther. 2020 Oct 19;14:4343-4362. doi: 10.2147/DDDT.S263898. eCollection 2020.
7
Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs.用于提高难溶性药物溶出度和生物利用度的药物分散技术。
Pharmaceutics. 2018 Jun 23;10(3):74. doi: 10.3390/pharmaceutics10030074.